RT Journal Article
SR Electronic
T1 The Parkinson’s Disease DNA Variant Browser
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.11.20172882
DO 10.1101/2020.08.11.20172882
A1 Jonggeol J. Kim
A1 Mary B. Makarious
A1 Sara Bandres-Ciga
A1 J. Raphael Gibbs
A1 Jinhui Ding
A1 Dena G. Hernandez
A1 Janet Brooks
A1 Francis P. Grenn
A1 Hirotaka Iwaki
A1 Andrew B. Singleton
A1 Mike A. Nalls
A1 Cornelis Blauwendraat
A1 on behalf of the International Parkinson’s Disease Genomics Consortium (IPDGC)
YR 2020
UL http://medrxiv.org/content/early/2020/08/14/2020.08.11.20172882.abstract
AB Parkinson’s disease (PD) is a genetically complex neurodegenerative disease with ~20 genes known to contain mutations that cause PD or atypical parkinsonism and 90 common genetic risk factors. Large-scale next-generation sequencing projects have revolutionized genomics research. Applying these data to PD, many genes have been reported to contain putative disease-causing mutations. In most instances, however, the results remain quite limited and rather preliminary, in large part because of an inability of any single group to validate findings in a large independent series of sequenced patients. We present here the Parkinson’s Disease Sequencing Browser: a Shiny-based web application that presents comprehensive summary-level frequency data from multiple large-scale genotyping and sequencing projects. The data is aggregated and involves a total of 102,127 participants, including 30,103 PD cases (including 1,650 proxy cases) and 72,024 controls. Our aim is to assist researchers on their search for PD-risk genes and variant candidates with an easily accessible and open summary-level genomic data browser for the PD research community, https://pdgenetics.shinyapps.io/VariantBrowser/.Competing Interest StatementMike A. Nalls' participation is supported by a consulting contract between Data Tecnica International and the National Institute on Aging, NIH, Bethesda, MD, USA, as a possible conflict of interest Dr. Nalls also consults for Illumina Inc, Lysosomal Therapeutics Inc, the Michael J. Fox Foundation and Vivid Genomics among others.Funding StatementWe would like to thank all of the subjects who donated their time and biological samples to be part of this study. The authors would also like to thank the Genome Aggregation Database (gnomAD) and the groups that provided exome and genome variant data to this resource. A full list of contributing groups can be found at https://gnomad.broadinstitute.org/about. Data used in the preparation of this article were obtained from the AMP PD Knowledge Platform. For up-to-date information on the study, https://www.amp-pd.org. AMP PD - a public-private partnership - is managed by the FNIH and funded by Celgene, GSK, the Michael J. Fox Foundation for Parkinson's Research, the National Institute of Neurological Disorders and Stroke, Pfizer, Sanofi, and Verily. Clinical data used in preparation of this article were obtained from the Fox Investigation for New Discovery of Biomarkers (BioFIND), the Harvard Biomarker Study (HBS), the Parkinson's Progression Markers Initiative (PPMI), and the Parkinson's Disease Biomarkers Program (PDBP). BioFIND is sponsored by The Michael J. Fox Foundation for Parkinson's Research (MJFF) with support from the National Institute for Neurological Disorders and Stroke (NINDS). The BioFIND Investigators have not participated in reviewing the data analysis or content of the manuscript. For up-to-date information on the study, visit michaeljfox.org/biofind. The Harvard NeuroDiscovery Biomarker Study (HBS) is a collaboration of HBS investigators. A full list of HBS investigator can be found at https://www.bwhparkinsoncenter.org/biobank/ and funded through philanthropy and NIH and Non-NIH funding sources. The HBS Investigators have not participated in reviewing the data analysis or content of the manuscript. PPMI - a public-private partnership - is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including AbbVie, Allergan, Amathus Therapeutics, Avid Radiopharmaceuticals, Biogen, BioLegend, Bristol-Myers Squibb, Calico, Celgene, Denali, GE Healthcare, Genentech, GlaxoSmithKline, Golub Capital, Handling's Therapeutics, Insitro, Janssen Pharmaceutica, Eli Lilly and Company, Lundbeck, Merck, Meso Scale Discovery, Neurocrine Biosciences, Pfizer, Piramal Imaging, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier, Takeda Pharmaceutical Company, Teva, UCB, Verily, and Voyager Therapeutics. The PPMI Investigators have not participated in reviewing the data analysis or content of the manuscript. For up-to-date information on the study, visit www.ppmi-info.org. Parkinson's Disease Biomarker Program (PDBP) consortium is supported by the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health. A full list of PDBP investigators can be found at https://pdbp.ninds.nih.gov/policy. The PDBP Investigators have not participated in reviewing the data analysis or content of the manuscript.. This work was supported by the Intramural Research Programs of the National Institute on Aging (NIA). This research has been conducted using the UK Biobank Resource under Application Number 33601. This study used the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health (http://hpc.nih.gov). The authors also would like to thank all members of the International Parkinson Disease Genomics Consortium (IPDGC). See for a complete overview of members, acknowledgments and funding http://pdgenetics.org/partners.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ExemptedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll aggregate data is freely available for use through the browser: https://pdgenetics.shinyapps.io/VariantBrowser/ The code for the browser is open source and available on the github repository here: https://github.com/kimjonggeolj/ipdgc_exome_browser/ https://github.com/kimjonggeolj/ipdgc_exome_browser/ https://pdgenetics.shinyapps.io/VariantBrowser/